跳至主要内容
临床试验/CTRI/2023/02/049628
CTRI/2023/02/049628尚未招募3 期

A randomized, double blind, comparative clinical study to compare and evaluate Efficacy and Safety of the Candimilt® 500 vaginal capsules (Miltonia Health Science Ltd) containing Clotrimazole 500 mg and the original drug Canesten® vaginal tablets containing Clotrimazole 500 mg, Bayer AG, Germany in patients with vulvovaginal candidiasis

MILTONIA HEALTH SCIENCE LTD0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Women with the symptoms of vulvovaginal candidiasis (based on symptoms and signs after speculum examination);
  • 2. Age at least 18 years;
  • 3. Capable of giving written informed consent;
  • 4. Agree to no intercourse for 8 days from the day of beginning of treatment;
  • 5. Agree not to douche or use any intra-vaginal products during the study period (including tampons, medications and devices);
  • 6. Non-pregnant Female patients aged 18 years or more and clinically diagnosed with vulvovaginal candidiasis were included;
  • 7. Capable of giving written informed consent and willing to follow the investigational study procedures and report AEs.
  • 8. Subjects must not be on their menstrual period on the day of screening and do not anticipate their period to begin during treatment (3 days);
  • 9. Subjects must be using an acceptable method of birth control, willing to refrain from sexual intercourse from the date of screening until the follow-up visit (approximately 7 days later);
  • 10. Willing to refrain from the use of any intravaginal/ vulvovaginal products (douches, spermicidal foams or gels, vaginal lubricants, etc) from the screening visit until the follow up visit;

排除标准

  • 1. Women will be excluded from the study if they are using or has used any topical or systemic medication, particularly antimicrobial agents over a 30-day period prior to the start of the investigation;
  • 2. Female patient has a positive pregnancy test at screening, is pregnant or lactating, or is planning to become pregnant during the study period;
  • 3. Previously diagnosed with human immunodeficiency virus (HIV) infection, having visible vaginal or cervical mass suspected cancer, and within six weeks of post-abortion or postpartum;
  • 4. Women who are currently or who will require treatment with anticoagulants, lithium, disulfiram, or neuromuscular blocking agents;
  • 5. Women are hypersensitive to clindamycin, clotrimazole or to any excipient in the drug formulation;
  • 6. Female patients who are breastfeeding or intending to breast feed during study period;
  • 7. Study will also exclude patients with history of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition;
  • 8. Patients with a history of seizure disorders;
  • 9. Patients with renal impairment (S. Creatinine > 1.5 times the normal reference values)
  • 10. Patients with hepatic impairment. [SGOT, SGPT, S. Bilirubin (Total) >1.5 times the normal reference values;
  • 11. History of uncontrolled Diabetes Mellitus;
  • 12. Patients with uncontrolled hypertension;
  • 13. Inability to comply with the protocol requirements;
  • 14. Participation in any other clinical trial within 3 months of registering in this trial;
  • 15. Patients receiving diuretics or related medicines;
  • 16. Post-menopausal women;
  • 17. Menstruating at the time of diagnosis;

研究者

发起方
MILTONIA HEALTH SCIENCE LTD

相似试验